NeuroVive Pharmaceutical AB P/E
What is the P/E of NeuroVive Pharmaceutical AB?
The P/E of NeuroVive Pharmaceutical AB is N/A
What is the definition of P/E?
Price to earnings ratio is the ratio of a company’s stock price to the company’s earnings per share calculated over trailing twelve months.
= previous day’s close / ttm EPS
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with p/e similar to NeuroVive Pharmaceutical AB
- HT&E has P/E of N/A
- Anfield has P/E of N/A
- Battalion Oil has P/E of N/A
- Ely Gold Royalties has P/E of N/A
- Kalray S.A has P/E of N/A
- GEDI Gruppo Editoriale S.p.A has P/E of N/A
- NeuroVive Pharmaceutical AB has P/E of N/A
- Yanchang Petroleum International has P/E of N/A
- GetSwift has P/E of N/A
- Entravision Communications has P/E of N/A
- Montanaro European Smaller Cos Trust Plc has P/E of N/A
- Hudson Resources has P/E of N/A
- Delta Resources has P/E of N/A